SNSE Sensei Biotherapeutics, Inc. Company Short-Term Debt

senseibio.com - graphic logo of issuer SNSE

Sensei Biotherapeutics (SNSE) faces uncertainty due to early-stage drug development and fierce competition. The short-term debt profile on the GURU.Markets terminal chart confirms this, while the value of 0.00 shows the latest liability figure. Clinical trial costs are weighing on the balance sheet, yet the success of the TMAb platform and merger potential remain the primary catalysts for the biotech's valuation growth.

SNSE Sensei Bio Short-Term Debt (07/04/2022 - 06/16/2026)

Analytical breakdowns and data insights for company Sensei Biotherapeutics Inc (SNSE)

- current quotes and average value forecast:
Price Chart Sensei Bio|SNSE - Average Forecast Price
- market capitalization data:
Market Value Sensei Biotherapeutics, Inc.|SNSE - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Sensei Biotherapeutics|SNSE - Total Stockholders' Equity|Market Capitalization to Book Value Ratio senseibio.com|SNSE - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Sensei Biotherapeutics|SNSE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Sensei Bio|SNSE - Aggregate Debt Obligations|Debts to Book Capitalization Sensei Biotherapeutics, Inc.|SNSE - Long-Term Debt Volume|Company Short-Term Debt Sensei Biotherapeutics|Quick Liquidity senseibio.com
- earnings and multiples data:
SNSE - Net Income
General company analysis:senseibio.com (SNSE)
Flagship merchandise of Sensei Biotherapeutics

For Sensei Biotherapeutics (SNSE), which relies on grants and research payments to develop anti-cancer vaccines, managing short-term debt is critical. By analyzing current liabilities, an investor assesses the total debt maturing within one year, which helps identify the risk of cash flow gaps and verify the company's compliance with strict liquidity covenants to ensure the preservation of invested capital.

Competitors of Sensei Biotherapeutics

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities minktherapeutics.com INKT|Werewolf Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Debts Immix Biopharma Inc. IMMX|ALXO - Company Short-Term Debt|CUE (Cue Biopharma Inc.) - Company Short-Term Indebtedness|pdsbiotech.com (PDSB) - Company Short-Term Debt|Short-Term Debt Sonnet BioTherapeutics Holdings (SONN)|Company Current Liabilities MAIA|LIMN - Short-Term Indebtedness|Company Current Liabilities LVTX (LAVA Therapeutics N.V.)|Amount of Current Liabilities NXTC|Company Short-Term Debts LPTX (Leap Therapeutics)|Company Short-Term Loans and Borrowings INTS|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)